| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9700530 | SPIL | Capsule dosage form of metoprolol succinate |
Jul, 2035
(11 years from now) | |
| US9504655 | SPIL | Capsule dosage form of metoprolol succinate |
Jul, 2035
(11 years from now) | |
Kapspargo Sprinkle is owned by Spil.
Kapspargo Sprinkle contains Metoprolol Succinate.
Kapspargo Sprinkle has a total of 2 drug patents out of which 0 drug patents have expired.
Kapspargo Sprinkle was authorised for market use on 26 January, 2018.
Kapspargo Sprinkle is available in capsule, extended release;oral dosage forms.
The generics of Kapspargo Sprinkle are possible to be released after 09 July, 2035.
Drugs and Companies using METOPROLOL SUCCINATE ingredient
Market Authorisation Date: 26 January, 2018
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
More Information on Dosage
KAPSPARGO SPRINKLE family patents
